Hsbc Holdings PLC Acquires 110,357 Shares of Amgen Inc. $AMGN

Hsbc Holdings PLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 7.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,537,251 shares of the medical research company’s stock after buying an additional 110,357 shares during the quarter. Hsbc Holdings PLC owned about 0.29% of Amgen worth $503,570,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in AMGN. Anfield Capital Management LLC boosted its position in shares of Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares during the last quarter. Dogwood Wealth Management LLC grew its holdings in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares in the last quarter. Board of the Pension Protection Fund bought a new position in shares of Amgen in the fourth quarter worth approximately $26,000. Manning & Napier Advisors LLC increased its position in shares of Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after purchasing an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC purchased a new stake in Amgen in the fourth quarter valued at approximately $33,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Performance

NASDAQ:AMGN opened at $337.60 on Friday. The company has a market capitalization of $182.21 billion, a price-to-earnings ratio of 23.49, a PEG ratio of 3.39 and a beta of 0.42. The business has a 50 day moving average of $340.71 and a 200 day moving average of $345.76. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen Inc. has a 1-year low of $267.83 and a 1-year high of $391.29.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the business earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, sell-side analysts predict that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on AMGN. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research report on Sunday, June 14th. Jefferies Financial Group assumed coverage on shares of Amgen in a report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price target on the stock. Royal Bank Of Canada raised their price objective on shares of Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Argus dropped their price objective on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a report on Wednesday, May 20th. Finally, The Goldman Sachs Group set a $389.00 target price on shares of Amgen in a research report on Friday, June 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Amgen currently has an average rating of “Hold” and an average target price of $354.42.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.85% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.